Sources and prices of newer ARVs: Prospects for Pricing and Availability XVI International AIDS Conference Satellite Session -- August 13, 2006 Médecins.

Slides:

Advertisements

Similar presentations

2 nd line and recent ARVs prices and access issues Carmen Pérez Casas Access Campaign MSF May 2006.

Advertisements

Key1 ARV Treatment Guidelines for a Public Health Approach Product Selection for HIV Treatment Vincent Habiyambere January 2006.

Access to paediatric ARV formulations Limitations due to regulations Experience from the field MSF.

Indicators for monitoring ARV treatment outcomes.

ART: The Basics William Aldis World Health Organization Bangkok, September 14, 2005.

Panorama of the pharmaceutical patenting and sanitary registration of ARVs drugs in Brazil: implications to access and to health industrial complex Pedro.

Patent Pools Increasing access to Medicines and Innovation Ellen ‘t Hoen MSF Access to Essential Medicines Campaign Barcelona 9 Dec

The new guidelines Dr Francois Venter Reproductive Health and HIV Research Unit University of the Witwatersrand Feb 2010.

Prescription and Use of Paediatric Antiretroviral Drugs (ARVs) for the Treatment of HIV in Children.

XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.

1 Clinton Foundation HIV/AIDS Initiative Pharmaceutical Services Team Engaging the ARV Marketplace to Optimize Outcomes for Patients February 14, 2006.

WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.

Access to essential medicines of the future Bernard Pécoul Director, Campaign for Access to Essential Medicines Médecins Sans Frontières.

Lagos, Nigeria: Is paying for HIV treatment bad for you? Comprehensive HIV-care in the General Hospital Lagos MSF-Holland/Germany.

UN Prequalification: UNICEF Perspective 5 th UN Prequalification stakeholders meeting 11th February 2009.

Access to Innovation: Making Generic Versions of Newer Antiretrovirals Affordable Focusing on middle income countries Leena Menghaney, MSF Access Camapign.

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

Medicines Patent Pool – Strictly Confidential, Not for Circulation Licensing Technology and Intellectual Property for the Development of Paediatric Formulations.

A very short introduction to patents & access to medicines.

Business environment for WHO prequalified medicines Arab Union of the Manufacturers of Pharmaceuticals and Medical Appliances Amman, Jordan, 13 June 2013.

TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.

How can Seychelles in future obtain affordable, good quality medicines for HIV/AIDS, Hepatitis C, cancer and other non-communicable diseases? Medical View.

Antiretrovirals Pricing: The Past, The Present, The Future Janice Lee.

Is the pricing of antiretrovirals equitable? Analysis of antiretroviral drug prices in 20 low and middle income countries Andrew Hill, Pharmacology and.

Programme Case Studies

Procuring High Quality ARVs at Internationally competitive Prices.

1 Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Impacts of TRIPS on access to care The post-2005 issues Benjamin CORIAT University Paris 13 and ANRS ANRS – MoH Brazil Satellite Meeting Mexico, August.

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.

When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.

1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Nov 2004Access to Paediatric ARV formulations ENSURING SECURE and RELIABLE SUPPLY and DISTRIBUTION SYSTEMS in DEVELOPING COUNTRIES, in the CONTEXT OF HIV/AIDS.

Getting the best treatment to the most people possible Enabling policies: threats & opportunities MSF Access Campaign.

1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.

What do we mean with ‘ there is no access to Paediatric ARV Formulations ’ ?

Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.

A Demand Forecasting Tool for Pediatric Antiretroviral Medications November 3, 2004.

Affordability of HIV/AIDS treatment in developing countries: an analysis of ARV drug price determinants Luis Sagaon Teyssier; Yves Arrighi; Boniface Dongmo.

Access to Paediatric ARV Formulations Provisions for Children.

Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.

Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.

Ellen ‘t Hoen Médecins sans Frontières

COST-EFFECTIVENESS OF THE WORLD HEALTH ORGANIZATION TREATMENT GUIDELINES IN AFRICA Eran Bendavid Philip Grant, Annie Talbot, Douglas Owens, Andrew Zolopa.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Treatment-Experienced Patients in Resource- Limited Settings Susan M. Graham Assistant Professor, Medicine.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

Universal Access: To what extent current mechanisms are appropriate and sustainable to maintain free of charge treatment? Compulsory Licensing in Brazil.

1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.

PMTCT around the world Where are we? PMTCT Experts Roundtable Geneva, June 2008.

Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.

IMPROVING ACCESS AND INNOVATION IN HIV THROUGH VOLUNTARY LICENSING: THE EXPERIENCE OF THE MEDICINES PATENT POOL ICASA – Harare, Zimbabwe Session on Innovation.

Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.

UNITAID actions and main achievements Investing in the quality of medicines XVII International AIDS Conference Satellite Forum WHO – Essential Medicines.

NEXT STEPS IN THE GLOBAL TREATMENT SIMPLIFICATION AGENDA THE ROLE OF PARTNERSHIPS Nathan Ford Department HIV and Global Hepatitis Programme WHO, Geneva.

The 2013 treatment guidelines and key implementation challenges Martina Penazzato IATT Normative Guidance Advisor HIV Department, WHO (Geneva, Switzerland)

Dr Dzintars Gotham MBBS BSc(Hons) on behalf of

Switch to PI/r monotherapy

MSF Access to Essential Medicines Campaign

Intellectual Property and Access to Affordable Medicines: TRIPS Plus

Justine Mirembe MD, MPH ICASA, 5th December 2011

How Advocacy can Influence Pricing & Policy

Characterizing the South Africa ART Market

Making medicines, diagnostics and other commodities more affordable

Drug Pricing Policies and Challenges

The Brazilian Experience

Juan Gonzalez Perez AIDS Healthcare Foundation

Forecasting for ARVs medicines

ART Use in Selected PEPFAR Countries Forecasting for ARVs to 2010 November 7-8, 2005 Rational Pharmaceutical Management Plus.

Switch to DRV/r monotherapy

Fabio Scano IUATLD Conference Paris, 2003

Presentation transcript:

Sources and prices of newer ARVs: Prospects for Pricing and Availability XVI International AIDS Conference Satellite Session -- August 13, 2006 Médecins Sans Frontières (MSF)

How to decrease current prices of newer ARVs?  Generic competition enabled Starting & Scaling Up ART: 99% price reductions of 1 st line treatments through generic competition from Simplification of treatment (esp. development and use of FDCs) WHO prequalification

Start ARTs: d4T/3TC/NVP Substitute for toxicity: TDF/FTC+EFV Switch after failure: ABC+ddI+LPV/r US$140/y LDCs US$ 1,700/y x5 x2.5 x12 US$689/y Middle- income US$365/y US$ 5,200/y x3 x4 x14 US$ 1,175/y

Impact of 2nd line Use on Project Cost: Treatment of 10% of patients uses up 60% of budget >7,000 patients on 1 st line

Cost recovery in Nigeria: Impact of user fees on access to Anti-Retroviral Therapy (MSF-H) Sources of financing ART (n=89) 72% of all ARV experienced interviewed people (n= 122) had interrupted ART: - 61% Finance - 14% Out of Gvt. Sotck - 6% Side effects - 19% Other reasons - Questionnaire to determine patients’ reasons for interrupting ART - Income analysis of patients through questionnaire

WHO recommendations WHO PQ generics Lowest differential price Lowest generic price NVP TC56951 AZT d4T45541 EFV 600mg ABC ATV0N/A EC ddI0288N/A LPV/r tablets0N/A ritonavir083N/A SQV 500mg0N/A TDF0207N/A FTC0N/A

Generic pipeline TDFTDF/3TC CIPLAUS$ 973*US$ 1,034* HETEROUS$ 360*N/A Other new drugs on the generic pipeline: - LPV/r tablets (heat-stable) - TDF/FTC - TDF/FTC/EFV - ATV * Prices still high and products not yet WHO prequalified

Conclusions Drug prices are still a major barrier to access Generic production is needed to ensure available and affordable drugs Generic production is feasible only if patents are not granted, esp. in key producing countries like India WHO and donors should address the need of affordable/quality drugs to be able ensure treatment for life for all people in need.